>>> Pfizer beats by $0.04, beats on revs; raises FY15 guidance

Pfizer beats by $0.04, beats on revs; raises FY15 guidance
  • Reports Q2 (Jun) earnings of $0.56 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $0.52; revenues fell 7.2% year/year to $11.85 bln vs the $11.42 bln consensus, which reflects operational growth of $125 million, or 1%, more than offset by the unfavorable impact of foreign exchange of $1.0 billion, or 8%. Excluding the impact of foreign exchange, adjusted diluted EPS(2) increased by approximately 6%.
  • Co issues in-line guidance for FY15, raises EPS to $2.01-2.07, excluding non-recurring items, from $1.95-2.05 vs. $2.06 Capital IQ Consensus; raises FY15 revs to $45-46 bln from $44-46 bln vs. $45.96 bln Capital IQ Consensus Estimate.

>>> UPS beats by $0.08, misses on revs; reaffirms FY15 EPS guidance

UPS beats by $0.08, misses on revs; reaffirms FY15 EPS guidance
  • Reports Q2 (Jun) earnings of $1.35 per share, $0.08 better than the Capital IQ Consensus of $1.27; revenues fell 1.2% year/year to $14.1 bln vs the $14.5 bln consensus.
    • All three segments improved operating profit and margin, led by International and Supply Chain and Freight performance. Currency exchange rates and lower fuel surcharges reduced total reported revenue growth. Pricing initiatives continue to drive base rates higher. Total company shipments increased 2.1% over the second quarter last year to 1.1 billion packages, led by U.S. Deferred Air products and International Export shipments.
    • US domestic rev +2% to $8.8 bln; operating profit +3% to $.2 bln; daily deliveries +1.8% due to slower pace of B2C growth.
  • Co reaffirms guidance for FY15, sees EPS of $5.05-5.30 vs. $5.18 Capital IQ Consensus Estimate.

>>> Arrow Elec beats by $0.04, beats on revs; guides Q3 EPS in-line, revs in-lin

Arrow Elec beats by $0.04, beats on revs; guides Q3 EPS in-line, revs in-line
Reports Q2 (Jun) earnings of $1.54 per share, excluding non-recurring items, $0.04 better than the Capital IQ Consensus Estimate of $1.50; revenues rose 2.7% year/year to $5.83 bln vs the $5.72 bln consensus.
  • Co issues in-line guidance for Q3, sees EPS of $1.40-1.52 vs. $1.42 Capital IQ Consensus Estimate; sees Q3 revs of $5.55-5.95 bln vs. $5.65 bln Capital IQ Consensus Estimate.

>>> Fresh Del Monte beats by $0.04, misses on revs (limited analyst coverage)

Fresh Del Monte beats by $0.04, misses on revs (limited analyst coverage)

Reports Q2 (Jun) comparable earnings of $1.20 per share, $0.04 better than the Capital IQ Consensus Estimate of $1.16; revenues rose 0.2% year/year to $1.13 bln vs the $1.15 bln consensus.
  • Bananas: Net sales for the second quarter increased 2% to $513.8 million, compared with $505.1 million in the second quarter of 2014, primarily driven by higher sales volume in the Company's North America and Asia regions, along with higher selling prices in the Company's Middle East region.

>>> Intrepid Potash misses by $0.09, misses on revs

Intrepid Potash misses by $0.09, misses on revs

Reports Q2 (Jun) loss of $0.08 per share, excluding non-recurring items, $0.09 worse than the Capital IQ Consensus Estimate of $0.01; revenues fell 33.6% year/year to $73.65 mln vs the $76.74 mln consensus. Adjusted EBITDA1 was $15.0 million, compared with $28.6 million a year ago.
  • Second quarter potash sales volume of 147,000 tons, decreased from last year's second quarter.
  • Intrepid`s average net realized sales price per ton was $358, which is $29 per ton higher than the comparable period in 2014 and slightly less than the first quarter of 2015.
  • The second quarter per ton cash operating cost of $224, a $36 increase from last year`s second quarter, is expected to be the high point for 2015.
Pot Ash Outlook
  • Production (tons) 440-460k
  • Sales (tons) 425-445k
  • Cash operating costs ($/ton) $190-205
  • Total Cogs ($/ton) $275-290

>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance
: ACPW +13.6%, KN +10.2%, GIG +9.6%, MSTR +7.8%, (announced the appointment of Phong Le as CFO effective on or about August 24, 2015; co also reported earnings), MZOR +6.8%, CMI +4.2%, SIRI +3.4%, RCII +3.1%, STO +2.9%, F +2.5%, VLRS +2.4%, BP +2.3%, MPWR +2.1%, UPS +2%, LH +1.9%, PFE +1.8%, NTLS+1.7%, ORAN +1.4%, CIT +1.3%, DHI +1.3%, WYN +1%, MRK +0.9%

Select metals/mining stocks trading higher: FCX +2.6%, BP +2.2%, MT +2.2%, BHP +2.1%, RIO +1.7%, GOLD +1.2%, NUE +1.1%, AA +1.0%

Fan Favorites showing strength with futures markets: NFLX +1.2%, TSLA +1.1%, AMZN +1%, AAPL +0.7%

Other news: SAEX +17.3% ( awarded a contract for ocean-bottom marine seismic data acquisition services, valued at ~$47 million ), DO +16.3% (still checking, may be in sympathy with STO earnings), SD +8.4% (announces receipt of notice from NYSE regarding continued listing standards - intends to consider available alternatives, potentially including a reverse stock split),JKS +3.8% (signs a three-year RMB3 billion line of credit agreement to support its PV project developments), REGN +3.7% (Regeneron Pharms and Sanofi (SNY) agree to jointly advance PD-1 and other new immuno-oncology antibodies), ASTI +3.4% (disclosed the mutual termination of its May agreement regarding the purchase and sale contract of its Thornton, Colorado headquarters building), SDRL +3.4% (in sympathy with STO earnings), SPWR +3% (announced that it has acquired 1.5 gigawatts of U.S. solar power plant development assets from Australia-based Infigen Energy), HZNP +1.6% (announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma and renal cell carcinoma), ACI +1.4% (announced that for administrative purposes it is postponing the previously announced one-for-ten reverse stock split of common stock), RDS.A +1.4% (in symp with BP), GILD +1.2% (ahead of earnings today)

Analyst comments: ITEK +4.7% (target raised to $29 from $9 at Piper Jaffray), BBRY +3% (upgraded to Equal-Weight from Underweight at Morgan Stanley), AEGR +2.1% (upgraded to Buy from Hold at Jefferies), PHG +1.5% (upgraded to Buy from Hold at Societe Generale), FB +0.6% (target raised to $117 at Axiom Capital ahead of earnings tomorrow afternoon)

>>> US Gapping down

Gapping down
In reaction to disappointing earnings/guidance
: AMKR -17.5%, BIDU -12.6%, CKEC -11.7%, COMM -5.7%, AVB -5.5%, AUDC -1.8%, CR -1.7%, TACO -1.4%, PRAH -1.4%, ALSN -1.3%, DD -1.2%

Other news: IMMU -45.6% (Belgium's UCB Phase 3 clinical trial program for Epratuzumab did not meet primary endpoint; Epratuzumab was licensed from IMMU), AMDA -30.3% (announced the FDA has requested co provide 24-month clinical performance data for pending 510(k) submission for the Valeo C Interbody with CsC Osteo-Conductive Scaffolding; co also provided in-line Q2 rev guidance), CARA -6.7% (commenced an underwritten public offering of shares of its common stock of up to $65 million), EGLT -5.4% (to offer and sell shares of its common stock in an underwritten public offering; size not disclosed), NYMX -1.6% (following 100% move higher yesterday), ADPT -1.5% (announces an offering of 2.75 mln shares of common stock; ~1.91 mln shares to be sold by co, ~843K shares to be sold by Sterling Partners shareholder group), YOKU -0.8% (following BIDU results), SINA -0.5% (following BIDU results)

Analyst comments: YELP -2.9% (downgraded to Hold from Buy at Deutsche Bank
)

(BFW) *RSA HAS NOT HELD TALKS W/ OR RECEIVED A PROPOSAL FROM ZURICH


BN 07/28 11:49 *RSA SAYS HOLDERS ARE ADVISED TO TAKE NO ACTION
BN 07/28 11:47 *RSA NOTES ZURICH ANNOUNCEMENT THAT CO IS EVALUATING RSA OFFER
BFW 07/28 11:47 *RSA HAS NOT HELD TALKS W/ OR RECEIVED A PROPOSAL FROM ZURICH
BN 07/28 11:46 *RSA INSURANCE: NO CERTAINTY OFFER WILL BE MADE
BN 07/28 11:46 *RSA HAS NOT HELD TALKS W/ OR RECEIVED A PROPOSAL FROM ZURICH
BN 07/28 11:46 *RSA NOT HELD TALKS WITH ZURICH
BN 07/28 11:46 *RSA INSURANCE ANNOUNCEMENT MADE WITHOUT CONSENT OF ZURICH
BN 07/28 11:46 *RSA INSURANCE IS EVALUATING A POTENTIAL OFFER FOR RSA
BN 07/28 11:46 *RSA INSURANCE BOARD NOTES ZURICH ANNOUNCEMENT
BN 07/28 11:46 *RSA INSURANCE GROUP STATEMENT RE POSSIBLE OFFER

RSA: RSA Insurance Group Plc: Statement re Possible Offer
2015-07-28 11:46:00.154 GMT

RSA: RSA Insurance Group Plc: Statement re Possible Offer

UK Regulatory Announcement

LONDON

RSA Insurance Group plc – Board notes Zurich announcement

The Board of RSA Insurance Group plc (“RSA”) notes the announcement by Zurich
Insurance Group (“Zurich”) that it is evaluating a potential offer for RSA.
RSA has not held talks with or received a proposal from Zurich and
shareholders are advised to take no action.

RSA looks forward to updating the market on trading performance and strategic
progress at the interim results announcement on 6 August 2015.

Statement re. Possible Offer

This announcement does not amount to an announcement of a firm intention to
make an offer. There can be no certainty that an offer will be made or as to
the terms of any such offer, should one be made.

This announcement has been made without the consent of Zurich.

In accordance with Rule 2.6(a) of the Code, Zurich is required, by not later
than 5.00 p.m. on 25 August 2015, to either announce a firm intention to make
an offer for RSA in accordance with Rule 2.7 of the Code or to announce that
it does not intend to make an offer, in which case the announcement will be
treated as a statement to which Rule 2.8 of the Code applies. This deadline
can be extended with the consent of the Panel in accordance with Rule 2.6(c)
of the Code.

In accordance with Rule 26.1 of the Code, a copy of this announcement will be
available at www.rsagroup.com.

The content of the website referred to in this announcement is not
incorporated into and does not form part of this announcement.

A further announcement will be made as and when appropriate.

Rule 2.10

In accordance with Rule 2.10 of the Code, RSA Insurance Group plc confirms
that as at the date of this announcement, it has in issue 1,016,868,658
Ordinary Shares of £1.00 each, and 125,000,000 Preference Shares of £1.00
each. The International Securities Identification Number (ISIN) of the
Ordinary Shares is GB00BKKMKR23. The International Securities Identification
Number (ISIN) of the Preference Shares is GB0008631391.

Disclosure requirements of the Takeover Code

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of
any class of relevant securities of an offeree company or of any securities
exchange offeror (being any offeror other than an offeror in respect of which
it has been announced that its offer is, or is likely to be, solely in cash)
must make an Opening Position Disclosure following the commencement of the
offer period and, if later, following the announcement in which any securities
exchange offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests
and short positions in, and rights to subscribe for, any relevant securities
of each of (i) the offeree company and (ii) any securities exchange
offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a)
applies must be made by no later than 3.30 pm (London time) on the 10th
business day following the commencement of the offer period and, if
appropriate, by no later than 3.30 pm (London time) on the 10th business day
following the announcement in which any securities exchange offeror is first
identified. Relevant persons who deal in the relevant securities of the
offeree company or of a securities exchange offeror prior to the deadline for
making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1%
or more of any class of relevant securities of the offeree company or of any
securities exchange offeror must make a Dealing Disclosure if the person deals
in any relevant securities of the offeree company or of any securities
exchange offeror. A Dealing Disclosure must contain details of the dealing
concerned and of the person's interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) the offeree company and
(ii) any securities exchange offeror, save to the extent that these details
have previously been disclosed under Rule 8. A Dealing Disclosure by a person
to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London
time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding,
whether formal or informal, to acquire or control an interest in relevant
securities of an offeree company or a securities exchange offeror, they will
be deemed to be a single person for the purpose of Rule 8.3.

Opening Position Disclosures must also be made by the offeree company and by
any offeror and Dealing Disclosures must also be made by the offeree company,
by any offeror and by any persons acting in concert with any of them (see
Rules 8.1, 8.2 and 8.4).

Details of the offeree and offeror companies in respect of whose relevant
securities Opening Position Disclosures and Dealing Disclosures must be made
can be found in the Disclosure Table on the Takeover Panel's website at
www.thetakeoverpanel.org.uk, including details of the number of relevant
securities in issue, when the offer period commenced and when any offeror was
first identified. If you are in any doubt as to whether you are required to
make an Opening Position Disclosure or a Dealing Disclosure, you should
contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129.

About RSA

With a 300 year heritage, RSA is a multinational quoted insurance group. RSA
has core operations in the UK, Scandinavia, Canada, Ireland, and Latin
America, and has the capability to write business in around 140 countries.
Focusing on general insurance, RSA has around 19,000 employees and, in 2014,
its net written premiums were £7.5 billion.

Enquiries:

Analysts   Press
Rupert Taylor Rea Louise Shield
Tel: +44 (0) 20 7111 7140 Tel: +44 (0) 20 7111 7047
 
Ryan Jones Kaidee Sibborn
Tel: +44 (0) 20 7111 7243 Tel: +44 (0) 20 7111 7137

View source version on businesswire.com:
http://www.businesswire.com/news/home/20150728005916/en/

Contact:

RSA Insurance Group Plc

-0- Jul/28/2015 11:46 GMT

>>> Chemours (DD spin off) guides Q2 ahead of call next week

Chemours (DD spin off) guides Q2 ahead of call next week

  • Co sees Q2 rev $1.5 bln vs $1.54 bln Capital IQ Consensus and segment operating earnings of $113 million.
    • Chemours stated that second quarter performance reflected a sequential improvement in titanium dioxide shipments over the first quarter despite a slow start to the North American coatings season. This volume improvement was offset by continued weakness in the TiO2 pricing environment and currency headwinds across the businesses.
    • Chemours expects to report second quarter 2015 financial results on a stand-alone basis on August 6th and will conduct a webcast conference call to review business performance.
    • Chemours anticipates additional cash flow improvements from the management of its asset portfolio. The Altamira expansion, which is expected to be completed in mid-2016, is anticipated to provide annual Adjusted EBITDA benefits of $20 million to $70 million. Once Altamira is complete, capital expenditures will decline from the peak of capital spending in 2014. The ramp up of the Opteon refrigerant product line will drive increased revenue and Adjusted EBITDA in the Fluoroproducts segment in each of the next three years. Chemours also continues to evaluate alternatives to improve the profitability of the Chemicals Solution segment.

>>> DuPont misses by $0.03, misses on revs; reduces outlook for Agriculture segm

DD US --> -1.8% PRe open

DuPont misses by $0.03, misses on revs; reduces outlook for Agriculture segment
Reports Q2 (Jun) earnings of $1.18 per share, $0.03 worse than the Capital IQ Consensus Estimate of $1.21; revenues fell 12.2% year/year to $8.88 bln vs the $8.97 bln consensus.
  • Co reduces guidance for FY15, sees EPS of $3.10, excluding $0.80 per share of anticipated full-year earnings from the Performance Chemicals segment, may not be comparable to $3.60 Capital IQ Consensus Estimate. This represents a $0.10 per share reduction from the prior outlook of $4.00 per share, which included the Performance Chemicals segment.
    • Consistent with continuing weakness in global agricultural markets, the company is reducing expectations for the year in its Agriculture segment due to weaker demand in global crop protection markets, reduced expectations for corn area in Latin America, and lower than expected soybean volumes in North America. The company continues to anticipate that the operational redesign will deliver savings of approximately $0.40 per share in 2015. As a result, the company expects operating earnings per share for 2015 to be about $3.10 per share for the full year